Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jaye Thompson"'
Autor:
Snehal Patel, Jaye Thompson, Mira Patel, F. Joseph Daugherty, C. Kent Osborne, Mothaffar Rimawi
Publikováno v:
Cancer Research. 83:OT2-10
Background: GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers, the combin
Autor:
Snehal S Patel, David B McWilliams, Christine T Fischette, Jaye Thompson, F. Joseph Daugherty, C. Kent Osborne, Mothaffar F Rimawi
Publikováno v:
Cancer Research. 82:OT1-18
Background: GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with an FDA-approved immunoadjuvant Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF, Sargramostim, Leukine) that stimulates an immune resp
Autor:
Snehal S Patel, David B McWilliams, Mira S Patel, Christine T Fischette, Jaye Thompson, F. Joseph Daugherty
Publikováno v:
Cancer Research. 82:P2-13
Background: Delayed type hypersensitivity (DTH) skin tests in the randomized, active-controlled, single-blinded, multicenter Phase IIb trial investigating GLSI-100 (GP2+GM-CSF) administered in the adjuvant setting to node-positive and high-risk node-
Autor:
Snehal S. Patel, David B. McWilliams, Mira S. Patel, Christine T. Fischette, Jaye Thompson, F Joseph Daugherty
Publikováno v:
Clinical Trials.
Autor:
Snehal S. Patel, Jaye Thompson, Mira S. Patel, F. Joseph Daugherty, C. Kent Osborne, Mothaffar F. Rimawi
Publikováno v:
Cancer Research. 82:CT232-CT232
Background: GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers. In a prosp
Publikováno v:
Cancer Research. 82:CT161-CT161
The authors did not submit an updated abstract. The original abstract should be considered final. Citation Format: Snehal S. Patel, David B. McWilliams, Mira S. Patel, Jaye Thompson, F. Joseph Daugherty. GP2 immune response a predictor of recurrence
Publikováno v:
Cancer Research. 82:CT166-CT166
The authors did not submit an updated abstract. The original abstract should be considered final. Citation Format: Snehal S. Patel, David B. McWilliams, Mira S. Patel, Jaye Thompson, F. Joseph Daugherty. Injection site reactions correlate to delayed
Publikováno v:
Journal of Clinical Oncology. 40:LBA550-LBA550
LBA550 Background: Injection site reactions (ISR) of booster injections in the randomized, active-controlled, single-blinded, multicenter Phase IIb trial of GLSI-100 (GP2+GM-CSF) administered in the adjuvant setting to node-positive and high-risk nod
Publikováno v:
Journal of Clinical Oncology. 40:e12519-e12519
e12519 Background: Delayed type hypersensitivity (DTH) skin tests to GP2 were conducted in the randomized, active-controlled, single-blinded, multicenter Phase IIb trial investigating GLSI-100 (GP2+GM-CSF) administered in the adjuvant setting to node
Autor:
Snehal Patel, Jaye Thompson, Mira Patel, F. Joseph Daugherty, C. Kent Osborne, Mothaffar F. Rimawi
Publikováno v:
Journal of Clinical Oncology. 40:TPS1110-TPS1110
TPS1110 Background: GP2 is a biologic nine amino acid peptide of the HER2/ neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers, t